The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Resveratrol inhibits nonalcoholic fatty liver disease in rats
Open accessAbstract
BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor alpha (TNF-alpha) production, lipid peroxidation and oxidative stress. METHODS: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-alpha in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured. RESULTS: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-alpha and MDA levels were significantly increased in the steatosis group (TNF-alpha; 33.4 +/- 5.2 vs 26.24 +/- 3.47 pg/ml and MDA; 9.08 +/- 0.8 vs 3.17 +/- 1.45 muM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05). CONCLUSION: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-alpha inhibition and antioxidant activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707 · cited 1×
“Other studies have also noted that resveratrol improved insulin sensitivity, lowered plasma glucose, and increased mitochondrial capacity in obese mice [27].”
Non‐alcoholic steatohepatitis: another disease of affluence
James, *., & Day, C. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00163-4 · Cited by 271
Francés, R., Chiva, M., Sánchez, E., González-Navajas, J. M., Llovet, T., Zapater, P., Soriano, G., Muñoz, C., Balanzó, J., Pérez-Mateo, M., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.018 · Cited by 54
Cited by
Novel insights of dietary polyphenols and obesity
Wang, S., Moustaid-Moussa, N., Chen, L., Mo, H., Shastri, A., Su, R., Bapat, P., Kwun, I., & Shen, C.-L. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.09.001 · Cited by 896
The role of mitochondria in insulin resistance and type 2 diabetes mellitus
Szendroedi, J., Phielix, E., & Roden, M. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.138 · Cited by 600
High-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F., García-Conesa, M., & Espín, J. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990407 · Cited by 449
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H.-Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019881 · Cited by 437
Metadata
- Authors
- Bujanda, L., Hijona, E., Larzabal, M., Beraza, M., Aldazabal, P., García-Urkia, N., Sarasqueta, C., Cosme, A., Irastorza, B., González, A., & Arenas, J. I.
- Venue
- BMC Gastroenterology
- Published
- 2008-09-09
- Volume
- 8
- Issue
- 1
- Pages
- 40-40
- ISSN
- 1471-230X (ISSN-L)
- OpenAlex
- W2044067781
- Cited by
- 225
- References
- 6
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resveratrol inhibits nonalcoholic fatty liver disease in rats. https://app.cochat.ai/papers/10.1186/1471-230x-8-40
- The paper
- Bujanda, L., Hijona, E., Larzabal, M., Beraza, M., Aldazabal, P., García-Urkia, N., Sarasqueta, C., Cosme, A., Irastorza, B., González, A., & Arenas, J. I. (2008). Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterology. https://doi.org/10.1186/1471-230x-8-40
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.